Kramer Levin Naftalis & Frankel LLP today launched the Bio Law Blog, which provides insights into intellectual property law and regulatory developments for biologic medicines. The blog is edited by Kramer Levin partners Irena Royzman, Ph.D., Jonathan S. Caplan and Hannah Lee.

“We started this blog to engage in a conversation about the rapidly developing US biosimilars pathway and the recent surge in approvals for cutting-edge biologic products, such as cell-based and gene therapies,” said Ms. Royzman. “These new biologic products are changing medicine and posing important intellectual property questions and challenges. We are excited to share with you our perspective as trial lawyers immersed in biology and biotech patent law during these transformative times for biologic medicines.”

The blog’s initial post, Biosimilar Litigation Trends and Lessons Learned in 2019, addresses biosimilar litigation trends and the current state of this dynamic area of law. Other topics the blog will cover include the:

  • New biologic products such as small interfering RNA (siRNA), and cell-based and gene therapies
  • Developments in written description and enablement law for antibodies
  • Impact of Section 101 on biotech discoveries
  • Increasing role of the Patent Trial and Appeal Board (PTAB) in reviewing biotech patents

Along with Royzman, Caplan and Lee, contributors to the blog will include the Kramer Levin life sciences team.